Literature DB >> 17761126

Irritable Bowel Syndrome: Bacterial Overgrowth--What's Known and What to Do.

Mark Pimentel1, Sheila Lezcano.   

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal condition whose cause remains unknown. Therefore, most of our effort in treating IBS has been based on a symptom approach. Recent evidence is beginning to suggest that subjects with IBS may have an alteration in gastrointestinal flora. Specifically, findings suggest that IBS patients have excessive bacteria in the small bowel, known as bacterial overgrowth. Although diagnostic testing for bacterial overgrowth is somewhat controversial, as there is no true gold standard test for bacterial overgrowth, antibiotic-based therapies for IBS are now shown to be very effective in treating IBS. Follow-up work in this area has even begun to demonstrate associative factors between gut bacteria and IBS that may explain the different types of IBS. The best example of this is the finding that methanogenic organisms in IBS patients are wholly associated with constipation-predominant IBS. It seems that the methane gas emitted during fermentation may have an influence on gut motility. In this review, the evidence for gut ecology associations in IBS is presented. A treatment algorithm also is proposed based on these findings. New areas of research in IBS such as gut bacteria are changing the treatment approach in IBS from a symptom-based style to one that is hypothesis driven.

Entities:  

Year:  2007        PMID: 17761126     DOI: 10.1007/s11938-007-0076-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  52 in total

1.  Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

Authors:  A Attar; B Flourié; J C Rambaud; C Franchisseur; P Ruszniewski; Y Bouhnik
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

2.  Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.

Authors:  M Di Stefano; S Malservisi; G Veneto; A Ferrieri; G R Corazza
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

3.  Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention.

Authors:  H Mertz; V Morgan; G Tanner; D Pickens; R Price; Y Shyr; R Kessler
Journal:  Gastroenterology       Date:  2000-05       Impact factor: 22.682

4.  Postinfectious irritable bowel syndrome--a meta-analysis.

Authors:  Heather A Halvorson; Carey D Schlett; Mark S Riddle
Journal:  Am J Gastroenterol       Date:  2006-08       Impact factor: 10.864

5.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

6.  Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study.

Authors:  Sally D Parry; Rosamund Stansfield; Diana Jelley; Wendy Gregory; Elizabeth Phillips; J Roger Barton; Mark R Welfare
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

7.  Methane production during lactulose breath test is associated with gastrointestinal disease presentation.

Authors:  Mark Pimentel; Andrew G Mayer; Sandy Park; Evelyn J Chow; Aliya Hasan; Yuthana Kong
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

8.  Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

Authors:  K R Neal; L Barker; R C Spiller
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome.

Authors:  J Kellow; O Y Lee; F Y Chang; S Thongsawat; M Z Mazlam; H Yuen; K A Gwee; Y T Bak; J Jones; A Wagner
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  The degree of breath methane production in IBS correlates with the severity of constipation.

Authors:  Soumya Chatterjee; Sandy Park; Kimberly Low; Yuthana Kong; Mark Pimentel
Journal:  Am J Gastroenterol       Date:  2007-04       Impact factor: 10.864

View more
  10 in total

1.  Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

Review 2.  The microbiome: stress, health and disease.

Authors:  Rachel D Moloney; Lieve Desbonnet; Gerard Clarke; Timothy G Dinan; John F Cryan
Journal:  Mamm Genome       Date:  2013-11-27       Impact factor: 2.957

3.  Measurement of oro-caecal transit time by magnetic resonance imaging.

Authors:  Edoardo Savarino; Vincenzo Savarino; Mark Fox; Giovanni Di Leo; Manuele Furnari; Elisa Marabotto; Lorenzo Gemignani; Luca Bruzzone; Alessandro Moscatelli; Chiara De Cassan; Francesco Sardanelli; Luca Maria Sconfienza
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

Review 4.  Irritable bowel syndrome: a concise review of current treatment concepts.

Authors:  Geoffrey C Wall; Ginelle A Bryant; Michelle M Bottenberg; Erik D Maki; Andrew R Miesner
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

5.  Incidence of predominant methanogenic flora in irritable bowel syndrome patients and apparently healthy controls from North India.

Authors:  S V Rana; S Sharma; S K Sinha; H Kaur; A Sikander; K Singh
Journal:  Dig Dis Sci       Date:  2008-05-21       Impact factor: 3.199

6.  Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use.

Authors:  Mohammed Saadi; Richard W McCallum
Journal:  Ther Adv Chronic Dis       Date:  2013-03       Impact factor: 5.091

Review 7.  Is irritable bowel syndrome an infectious disease?

Authors:  John Richard Thompson
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 8.  Antibiotics for irritable bowel syndrome: rationale and current evidence.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Curr Gastroenterol Rep       Date:  2012-10

9.  A Systematic Review of Technical Parameters for MR of the Small Bowel in non-IBD Conditions over the Last Ten Years.

Authors:  Jingyu Lu; Ziling Zhou; John N Morelli; Hao Yu; Yan Luo; Xuemei Hu; Zhen Li; Daoyu Hu; Yaqi Shen
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

Review 10.  Abdominal bloating: pathophysiology and treatment.

Authors:  A Young Seo; Nayoung Kim; Dong Hyun Oh
Journal:  J Neurogastroenterol Motil       Date:  2013-10-07       Impact factor: 4.924

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.